Insulet Corporation · NASDAQ:PODD
Insulet — The Raymond James & Associates 45th Annual Institutional Investors Conference 2024
16 slides from Insulet's conference presentation, Mar 5, 2024
Slide 1: Insulet Corporation – Raymond James Conference
Insulet Corporation Raymond James Conference Kimsue Podder since 2023 Eric Benjamin, EVP, Chief Product & Customer Experience Officer March 2024
Slide 2: Forward Looking Statement; Non-GAAP Financial Measures
Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments a
Slide 3: Driving Continued Growth and Success
Driving Continued Growth and Success 1 Achieving our mission with market-leading innovation 2 Strong fundamentals powering financial results 3 Penetrating and leading in the diabetes market Eloise Podder 4 Realizing the Omnipod 5 opportunity since 2023 3
Slide 4: Achieving Our Mission with Market-Leading Innovation
Achieving Our Mission with Market-Leading Innovation Simplify Life for People with Diabetes Market-Leading • Omnipod platform Technology • Reduce burden • Improve outcomes Market-Leading Competitive Advantages Revenue Growth • Skilled talent with deep in-house expertise • Robust innovation roadmap •
Slide 5: Strong Fundamentals Powering Financial Results
Strong Fundamentals Powering Financial Results Maximizing Investing Expanding Revenue for Growth Operating Margins ~25% ~18% +~7pts Revenue CAGR R&D Expense CAGR Adjusted Operating Margin 2018 - 20231 2018 - 2023 2018 - 20232 Powered by Omnipod 5, the Most Prescribed AID3 System in 2023 in the U.S.4
Slide 6: Well-Positioned for the Massive Market Opportunity
Well-Positioned for the Massive Market Opportunity 537M 1.3B 2022 2050 People with Diabetes Worldwide1,2 ~64M Requiring Insulin Worldwide1 ~11M3 Total Addressable Market3 45% 55% Type 1 Insulin Intensive Type 2 +3M U.S. Basal Opportunity (Future TAM opportunity) 1. Source: IDF Atlas 10th Edition. 2.
Slide 7: Omnipod is Unlocking the Largest Market Opportunity
Omnipod is Unlocking the Largest Market Opportunity “Omnipod has been a game changer! No Conventional Multiple Daily VS. more multiple Insulin Pump Injections (MDI) daily injections!” –Ximena’s Mom ~5% ~95% Ximena Podder since 2023 of the global market of the global market One pod replaces opportuni
Slide 8: Winning on All Dimensions with Omnipod
Winning on All Dimensions with Omnipod 5 The Omnipod Platform + Omnipod 5 with AID = Obvious • No needles or tubes • Cutting-edge algorithm using micro-dose technology Choice • Discreet, wearable, disposable • Industry-leading time in range • Pay-as-you-go economics for customers and payors • Very f
Slide 9: Omnipod 5 Simplifies Diabetes Management
Omnipod 5 Simplifies Diabetes Management SIMPLICITY MEETS OUTCOMES Driving Outcomes Automated, continuous glucose monitoring (CGM) integration World-Class User Experience Tubeless, smart-phone controlled, simple interface Data & Connectivity Always cloud connected PIPELINE Advanced Performance with
Slide 10: Innovation Drives Horizons of Growth
Innovation Drives Horizons of Growth Lead the Industry with Novel Innovations Expand TAM Drive Omnipod 5 Growth • Continually improve customer experience and ease of use • Innovate and expand product indications and global presence • Next-generation algorithms • Expand the Omnipod 5 platform • Omnip
Slide 11: Driving Continued Growth and Success
Driving Continued Growth and Success 1 Achieving our mission with market-leading innovation 2 Strong fundamentals powering financial results 3 Penetrating and leading in the diabetes market Holly Podder 4 Realizing the Omnipod 5 opportunity since 2017 11
Slide 12: Thank You
Thank You Insulet
Slide 13: Appendix
Appendix Insulet
Slide 14: Reconciliation of Non-GAAP Measures Revenue (continued)
Reconciliation of Non-GAAP Measures Revenue (continued) Year Ended December 31, 2023 2022 Percent Change Currency Impact Constant Currency U.S. Omnipod $1,251.0 884.8 41.4% -% 41.4% International Omnipod 410.1 363.0 13.0% 1.6% 11.4% Total Omnipod 1,661.1 1,247.8 33.1% 0.4% 32.7% Drug Delivery 36.0 5
Slide 15: Reconciliation of Non-GAAP Measures Revenue
Reconciliation of Non-GAAP Measures Revenue Quarter Ended December 31, 2023 2022 Percent Change Currency Impact Constant Currency U.S. Omnipod $394.6 276.2 42.9% -% 42.9% International Omnipod 106.4 90.2 18.0% 5.5% 12.5% Total Omnipod 501.0 366.4 36.7% 1.3% 35.4% Drug Delivery 8.8 3.3 166.7% -% 166.
Slide 16: Reconciliation of Non-GAAP Measures Operating Margin
Reconciliation of Non-GAAP Measures Operating Margin Year Ended December 31, 2023 (dollars in millions) Gross Profit Percent of Revenue Operating Income Percent of Revenue GAAP $1,159.9 68.3% $220.0 13.0% Voluntary medical device corrections1 (11.5) (11.5) Non-GAAP $1,148.4 67.7% $208.5 12.3% The Co
Insulet — The Raymond James & Associates 45th Annual Institutional Investors Conference 2024 on 6ix